In this issue:
Clinically orientated recommendations from the EADV for CHE
Meta-analysis suggests upadacitinib is the most efficacious for AD
SCS commonly prescribed for AD against clinical guidelines
LIBERTY-CINDU CUrIADS fails to find a benefit to dupilumab in cold urticaria
Promising efficacy for temtokibart in AD
Abrocitinib bests upadacitinib & baricitinib for AD in real-world
Topical benvitimod suitable for long-term maintenance of CHE
Upadacitinib effective for AD sub-optimally controlled with dupilumab
Positive behavioural changes with omalizumab in solar urticaria
High long-term persistence rates with dupilumab for AD
Please login below to download this issue (PDF)